RMD - ResMed Non-GAAP EPS of $1.88 beats by $0.10 revenue of $1.2B beats by $50M January, 24 2024 04:10 PM ResMed Inc. 2024-01-24 16:10:05 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards ResMed Q2 2024 Earnings Preview ResMed product recall classified as most serious by FDA (update) For further details see: ResMed Non-GAAP EPS of $1.88 beats by $0.10, revenue of $1.2B beats by $50M